This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coelmont, L.
Right arrow Articles by Neyts, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coelmont, L.
Right arrow Articles by Neyts, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3444-3446, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00372-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine

Lotte Coelmont,1 Jan Paeshuyse,1 Marc P. Windisch,2 Erik De Clercq,1 Ralf Bartenschlager,2 and Johan Neyts1*

Rega Institute for Medical Research, KULeuven, 3000 Leuven, Belgium,1 Department of Molecular Virology, University of Heidelberg, 69120 Heidelberg, Germany2

Received 27 March 2006/ Returned for modification 8 May 2006/ Accepted 31 July 2006

Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.

* Corresponding author. Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32-16-337341. Fax: 32-16-337340. E-mail: johan.neyts{at}rega.kuleuven.be.

Antimicrobial Agents and Chemotherapy, October 2006, p. 3444-3446, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00372-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Coelmont, L., Kaptein, S., Paeshuyse, J., Vliegen, I., Dumont, J.-M., Vuagniaux, G., Neyts, J. (2009). Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors. Antimicrob. Agents Chemother. 53: 967-976 [Abstract] [Full Text]  
  • Koziel, M. J., Peters, M. G. (2007). Viral Hepatitis in HIV Infection. NEJM 356: 1445-1454 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»